Current Treatment Options in Neurology

, Volume 12, Issue 4, pp 309–320 | Cite as

Newly Diagnosed High-Grade Gliomas

Neuro-oncology (Neoplasms)

Opinion statement

High-grade or malignant gliomas are aggressive cancers. The World Health Organization (WHO) grading system recognizes grade III and grade IV primary brain tumors of astrocytic, oligodendroglial, or mixed lineage. Identification of these tumors is prompted by symptoms such as insidious headaches, seizures, or focal weakness or numbness, with imaging findings of an enhancing mass lesion. Following surgery, radiation therapy has been known since the late 1970s to improve survival in malignant gliomas. More recently, the concurrent use of temozolomide (TMZ) and radiation therapy and the incorporation of bevacizumab have offered hope for patients with glioblastoma (WHO grade IV glioma). Although radiation is regularly used for up-front treatment of grade III gliomas, the role of chemotherapy is still being refined. In the past, patients with high-grade gliomas were often referred to a dedicated neuro-oncology center, but with improved outcomes and increased survival, these patients now are often treated by community oncologists. We believe substantial changes will develop with pending investigations that refine the dose and length of TMZ treatment, define specialized treatment for the elderly, and assess efficacy of bevacizumab in up-front therapy. The field is also conducting the required studies to define the role of chemotherapy for grade III malignant gliomas. These promising advances are needed as most patients with high-grade gliomas still succumb to their disease.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.••
    Stupp R, Hegi ME, Mason WP, et al.: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459–466. CrossRefPubMedGoogle Scholar
  2. 2.
    Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996.CrossRefPubMedGoogle Scholar
  3. 3.
    CBTRUS: CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL, 2010. Available at
  4. 4.
    American Cancer Society: Cancer Facts and Figures 2009. Atlanta: American Cancer Society; 2009.Google Scholar
  5. 5.
    Jukich PJ, McCarthy BJ, Surawicz TS, et al.: Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro Oncol 2001, 3:141–151.CrossRefPubMedGoogle Scholar
  6. 6.
    Walter AW, Hancock ML, Pui CH, et al.: Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children’s Research Hospital. J Clin Oncol 1998, 16:3761–3767.PubMedGoogle Scholar
  7. 7.
    Inskip PD, Tarone RE, Hatch EE, et al.: Cellular-telephone use and brain tumors. N Engl J Med 2001, 344:79–86.CrossRefPubMedGoogle Scholar
  8. 8.
    Salvatore JR, Weitberg AB, Mehta S: Nonionizing electromagnetic fields and cancer: a review. Oncology (Williston Park) 1996, 10:563–570; discussion 573–564, 577–568.Google Scholar
  9. 9.
    Louis DN, Ohgaki H, Wiestler OD, et al.: WHO Classification of Tumours of the Central Nervous System (IARC WHO Classification of Tumours), edn 4. Geneva, Switzerland: World Health Organization; 2007.Google Scholar
  10. 10.•
    Yan H, Parsons DW, Jin G, et al.: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360:765–773. CrossRefPubMedGoogle Scholar
  11. 11.
    Louis DN, Holland EC, Cairncross JG: Glioma classification: a molecular reappraisal. Am J Pathol 2001, 159:779–786.PubMedGoogle Scholar
  12. 12.
    Hildebrand J, Lecaille C, Perennes J, Delattre JY: Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005, 65:212–215.CrossRefPubMedGoogle Scholar
  13. 13.
    Hoffman WF, Levin VA, Wilson CB: Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 1979, 50:624–628.CrossRefPubMedGoogle Scholar
  14. 14.
    Brandes AA, Franceschi E, Tosoni A, et al.: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192–2197.CrossRefPubMedGoogle Scholar
  15. 15.
    Chamberlain MC, Glantz MJ, Chalmers L, et al.: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81–83.CrossRefPubMedGoogle Scholar
  16. 16.
    Ruben JD, Dally M, Bailey M, et al.: Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499–508.PubMedGoogle Scholar
  17. 17.
    Taal W, Brandsma D, de Bruin HG, et al.: Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405–410.CrossRefPubMedGoogle Scholar
  18. 18.
    Hirai T, Murakami R, Nakamura H, et al.: Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 2008, 29:1505–1510.CrossRefPubMedGoogle Scholar
  19. 19.
    Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20:1375–1382.CrossRefPubMedGoogle Scholar
  20. 20.
    Yung WK, Albright RE, Olson J, et al.: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588–593.CrossRefPubMedGoogle Scholar
  21. 21.
    Yung WK, Prados MD, Yaya-Tur R, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762–2771.PubMedGoogle Scholar
  22. 22.
  23. 23.
    Mirimanoff RO, Gorlia T, Mason W, et al.: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006, 24:2563–2569.CrossRefPubMedGoogle Scholar
  24. 24.
    NCT00943826 h. Accessed January 2010.
  25. 25.
    Ananthnarayan S, Bahng J, Roring J, et al.: Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 2008, 88:339–347.CrossRefPubMedGoogle Scholar
  26. 26.
    Derr RL, Ye X, Islas MU, et al.: Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2009, 27:1082–1086.CrossRefPubMedGoogle Scholar
  27. 27.
    Roa W, Brasher PM, Bauman G, et al.: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583–1588.CrossRefPubMedGoogle Scholar
  28. 28.
    Keime-Guibert F, Chinot O, Taillandier L, et al.: Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527–1535.CrossRefPubMedGoogle Scholar
  29. 29.
    Chinot OL, Barrie M, Frauger E, et al.: Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208–2214.CrossRefPubMedGoogle Scholar
  30. 30.
    Glantz M, Chamberlain M, Liu Q, et al.: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262–2266.CrossRefPubMedGoogle Scholar
  31. 31.
    Kimple RJ, Grabowski S, Papez M, et al.: Glioblastoma in the elderly: Radiation, chemoradiation, and supportive care [abstract]. J Clin Oncol 2008, 26:Abstract 20738.Google Scholar
  32. 32.
    Hegi ME, Diserens AC, Gorlia T, et al.: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997–1003.CrossRefPubMedGoogle Scholar
  33. 33.
    Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350–1354.CrossRefPubMedGoogle Scholar
  34. 34.
    Hegi ME, Diserens AC, Godard S, et al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871–1874.CrossRefPubMedGoogle Scholar
  35. 35.
    Weller M, Stupp R, Reifenberger G, et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6:39–51.Google Scholar
  36. 36.•
    van den Bent MJ, Dubbink HJ, Sanson M, et al.: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol 2009, 27:5881–5886. CrossRefPubMedGoogle Scholar
  37. 37.
    Wick W, Hartmann C, Engel C, et al.: NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009, 27:5874–5880.CrossRefPubMedGoogle Scholar
  38. 38.
    Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988, 23:360–364.CrossRefPubMedGoogle Scholar
  39. 39.
    Bigner SH, Matthews MR, Rasheed BK, et al.: Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 1999, 155:375–386.PubMedGoogle Scholar
  40. 40.
    Cairncross JG, Ueki K, Zlatescu MC, et al.: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473–1479.CrossRefPubMedGoogle Scholar
  41. 41.
    Smith JS, Perry A, Borell TJ, et al.: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636–645.PubMedGoogle Scholar
  42. 42.
    Cairncross G, Berkey B, Shaw E, et al.: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006, 24:2707–2714.CrossRefPubMedGoogle Scholar
  43. 43.
    van den Bent MJ, Carpentier AF, Brandes AA, et al.: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006, 24:2715–2722.CrossRefPubMedGoogle Scholar
  44. 44.
    Vogelbaum MA, Berkey B, Peereboom D, et al.: Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro Oncol 2009, 11:167–175.CrossRefPubMedGoogle Scholar
  45. 45.
    Abrey LE, Louis DN, Paleologos N, et al.: Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 2007, 9:314–318.CrossRefPubMedGoogle Scholar
  46. 46.
    Prados MD, Scott C, Curran Jr WJ, et al.: Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999, 17:3389–3395.PubMedGoogle Scholar
  47. 47.
    Levin VA, Silver P, Hannigan J, et al.: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990, 18:321–324.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Medicine, Section of Hematology/OncologyUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Department of NeurosciencesMedical University of South CarolinaCharlestonUSA

Personalised recommendations